CSF3R复合突变通过PIM激酶过表达驱动高增殖性白血病
本研究探讨CSF3R复合突变(约25%的CNL患者携带同一等位基因上的两个突变)的分子特征,发现复合突变较单突变诱导更强的白血病增殖,显著增强STAT5和ERK1/2活化,蛋白质组学显示MYC和mTOR通路富集,PIM1为差异表达最显著的蛋白,PIM激酶转录增加 stabilizes MYC蛋白并激活MYC驱动转录程序,PIM抑制剂可逆转MYC稳定化,在人类细胞系和CNL患者样本中显示治疗潜力。
要点
- CSF3R复合突变较单突变诱导更强的白血病增殖和STAT5/ERK1/2活化。
- PIM1是复合突变细胞中差异表达最显著的蛋白,PIM激酶转录增加稳定MYC蛋白。
- PIM抑制剂可逆转MYC稳定化,在CNL患者样本中显示治疗潜力。
核心结论
- CSF3R复合突变通过PIM激酶过表达稳定MYC蛋白,驱动高增殖性白血病,PIM抑制为该类CNL提供潜在靶向治疗策略。
研究设计与样本
- 本研究为实验性机制研究,使用细胞模型、蛋白质组学方法、人类细胞系和CNL患者样本,未明确报告样本量。
主要发现
- CSF3R复合突变较单突变诱导高增殖性白血病,并显著增强STAT5和ERK1/2活化。
- 蛋白质组学显示复合突变细胞中MYC和mTOR通路富集,PIM1为差异表达最显著的蛋白。
- 高STAT活性复合突变细胞中PIM激酶转录增加,PIM1转录水平在人类CSF3R突变队列中高。
- 高PIM水平稳定MYC蛋白并激活MYC驱动白血病转录程序,PIM抑制剂逆转MYC稳定化。
临床怎么用
- PIM抑制可能作为CSF3R复合突变CNL患者的靶向治疗策略,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colony Stimulating Factor 3 Receptor (CSF3R) mutations are the molecular hallmark of chronic neutrophilic leukemia (CNL). A subset of these patients (~25%) have two mutations in CSF3R on the same allele. These "compound" CSF3R mutations include both an activating point mutation and a cytoplasmic truncating mutation. While compound mutations are prevalent, we have a limited understanding of their molecular characteristics. In this study, we interrogated the mechanisms driving the evolution of compound mutations. We found that CSF3R compound mutations induce a hyperproliferative leukemia compared to single mutations. Compound mutations also markedly enhance activation of STAT5 and ERK1/2 downstream of CSF3R. Utilizing a proteomics approach, we identified enrichment of MYC and mTOR pathways in compound mutant-cells. The most differentially expressed protein in this dataset was the kinase PIM1. We find that in CSF3R compound mutant-cells with high STAT activity there is increased transcription of PIM kinases. We further validated that PIM1 transcript levels are high in a human CSF3R mutant-cohort. High PIM levels drive stabilization of MYC protein, and the downstream activation of MYC-driven leukemogenic transcriptional programs. Indeed, inhibitors of PIM reverse MYC stabilization. Finally, we show promising therapeutic potential for PIM-inhibition in CSF3R mutant-disease using both human cell lines and CNL patient samples. Together, these findings uncover a novel and targetable vulnerability in CSF3R compound mutant-CNL, thus opening a new avenue of treatment for patients with this devastating disease.
引用
- Maniaci BN, Porter JE, Carlson HL, et al. CSF3R compound mutations produce a hyperproliferative leukemia driven by overexpression of PIM kinases. Blood. 2026. PMID: 42814612. doi:10.1182/blood.2026034085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。